GO
Loading...

Enter multiple symbols separated by commas

Merck & Co Inc

More

  • Stocks Close Lower But Pare Some Losses Wednesday, 13 Aug 2008 | 3:01 PM ET

    Stocks closed lower, hurt by rising oil prices and fresh worries about the financial sector, though the market ended off its lows for the day.

  • Stocks Suffer as Retail Slips, Deere Misses Wednesday, 13 Aug 2008 | 9:47 AM ET

    Stocks opened lower amid signs that the consumer was buying fewer goods that will cost more in the future.

  • Elan On Eight-Eight-Oh-Eight, Etc. Friday, 8 Aug 2008 | 11:47 AM ET
    Elan

    The Elanians have been pretty quiet in the wake of last week's bad news. and the stock getting about a two-thirds haircut. And I don't mean to rub salt in the wound.

  • Lightning Round OT: Merck, First Solar and More Monday, 28 Jul 2008 | 7:16 PM ET

    The Lightning Round is extended in this CNBC.com exclusive feature.

  • Dow Loses 1.1% for Week as Banks Skid Friday, 25 Jul 2008 | 6:05 PM ET

    Stocks pulled off modest gains Friday as enthusiasm for some better-than-expected economic reports outshined a warning from S&P of a possible downgrade on Fannie Mae and Freddie Mac.

  • Quick Market Stats: Week of 7/21 Friday, 25 Jul 2008 | 5:24 PM ET

    On a heavy earnings week with over 30% of the S&P 500 reporting, the markets end the week mixed on positive economic data and a decline in oil prices to an almost two-month low.  The Dow and S&P are both down for the week while the NASDAQ ends the week up about 1.2%. 

  • The State of Statins & Stents Friday, 25 Jul 2008 | 11:14 AM ET
    Heart Stent

    Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.

  • Pfizer Profit Doubles on Drug Sales, Lower Costs Wednesday, 23 Jul 2008 | 8:55 AM ET
    pfizer_hq.jpg

    Pfizer Wednesday said quarterly earnings more than doubled on higher sales of its prescription drugs and lower expenses, but its Chantix quit-smoking drug lost more than a third of its U.S. sales amid safety concerns.

  • Pharma: May Cause Nausea, Dry Mouth Tuesday, 22 Jul 2008 | 6:30 PM ET

    If only Merck could develop a treatment for this malady...

  • Stocks Rally to the Finish With Banks in the Lead Tuesday, 22 Jul 2008 | 4:59 PM ET

    Stocks surged in the final hour of trading as a sharp drop in oil prices and an analyst note prompted a late rally in financials. The Nasdaq eked out a gain but investors still punished select techs, including Apple and Texas instruments after the firms dispatched disappointing results.

  • Oil Boosts Stocks but Techs Weigh on Market Tuesday, 22 Jul 2008 | 3:34 PM ET

    Stocks advanced, buoyed by a sharp drop in oil prices, but technology stocks dragged on the market after disappointing earnings from Apple and Texas Instruments.

  • Merck And "Sex and the City" Strategy: Did It Work? Tuesday, 22 Jul 2008 | 2:38 PM ET
    Sex and The the City

    Recently I blogged about Merck advertising its cervical cancer vaccine Gardasil to a captive audience during trailers for the "Sex and the City" movie.

  • Oil Buoys Stocks but Techs Drag Tuesday, 22 Jul 2008 | 2:01 PM ET

    Stocks advanced, buoyed by a sharp drop in oil prices, but technology stocks dragged on the market after disappointing earnings from Apple and Texas Instruments.

  • Farrell: Touching Bottom in this Bear Market? Tuesday, 22 Jul 2008 | 10:56 AM ET
    Vince Farrell

    The average bear market shows a decline of 30%, but then has an average 30% plus bounce when the bottom is reached. We are off more than 20% so it's possible the end is in sight.

  • vytorin_logo.jpg

    Yesterday while covering the press conference about the new study on Merck and Schering-Plough's Vytorin I quoted the lead researcher, Dr. Terje Pedersen of Ulleval University Hospital in Oslo, Norway, who said--and this is a direct quote: "However, we had a disturbing finding when we looked at safety."

  • All Signs Point To Weaker Open Monday, 21 Jul 2008 | 6:08 PM ET
    graphic_word_ofthe_street.jpg

    Based on the action after hours it looks like a rough open on Tuesday. What's the "Word on the Street?"

  • Banks Snap Winning Streak, Stocks Slide Monday, 21 Jul 2008 | 5:22 PM ET

    Stocks slipped as the bank rally that has stretched four sessions appeared to run out of steam ahead of Wachovia's report. Merck fell following disappointing results from a cholesterol-drug study.

  • Schering-Plough Profit Falls but Tops Forecasts Monday, 21 Jul 2008 | 5:09 PM ET
    schering_plough_earnings.jpg

    Schering-Plough, whose shares fell earlier after its Vytorin cholesterol fighter failed another study, said its earnings fell 23 percent but beat forecasts.

  • Merck Limits Guidance; Posts In-Line Results Monday, 21 Jul 2008 | 5:03 PM ET
    merck_earnings.jpg

    Merck  on Monday said it was not providing long-time financial forecasts as it assesses the impact of another failed study result for its Vytorin cholesterol fighter, which it produces with Schering Plough.

  • Bulls Find No Joy In After Hours Session Monday, 21 Jul 2008 | 5:03 PM ET

    1) American Express reported a notable miss ($0.56 vs. expectations of $0.83), and it's not hard to see where the bulk of the miss came from. a $600 million ($374 after-tax) addition to U.S. lending credit reserves.